Pharma Or Biotech – Which Innovates Better?
This article was originally published in The Pink Sheet Daily
Executive Summary
San Diego CEOs and BIOCOM head sit down with "The Pink Sheet" DAILY.
You may also be interested in...
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.
Some Investors Depressed About Biovail’s Buyout Of U.S. Wellbutrin Rights
Dividend cut also hurts shares, as the company continues its move toward the neurology space.